DCVC

Activity from announced rounds

Activity in this selectionOct 27, 2026 · AI · Jul 30, 2026

DCVC is an investment firm identified by TypeSafe AI as an existing investor and by its own communications as a backer of Shennon Biotechnologies.

Recorded funding activity

TypeSafe turns unstructured inputs into typed decisions and probability scores for automated software. Shennon develops T-cell engager therapies for solid tumors. Separate TypeSafe financings remain separate events under one investor history.

Sources
Rounds participated in
4
Confirmed lead rounds
2
1 roles undisclosed
New companies
3
First participation on record · 1 follow-on
Funding in participating rounds
$1B
4 disclosed · full round size, not this investor’s share

By stage

Seed3
Series A1

By primary sector

AI3
Healthtech1

By country

United States3
United Kingdom1

Rounds

4 in this selection
BioStack

BioStack builds clinical data pipelines and realistic training environments for healthcare and drug-discovery AI.

$9.5MSeed
Lead
TypeSafe AI

Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.

$870MSeries A
Participant
TypeSafe AI

Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.

$40MSeed
Lead
Callosum

Software infrastructure allowing AI workloads to run across different chips and models

$100MSeed
Role not disclosed